Project description:To investigate the heterogeneity of lung CD140a+ mesenchymal cells (fibroblasts) and identify the specific lung fibroblast subset, we purified CD140a+ lung cells using CD140a-EGFP reporter mice for a higher-resolution scRNA-seq.
Project description:To investigate the heterogeneity of lung stromal cells and identify the specific lung stromal subset, we performed single cell RNA-sequencing (scRNA-seq) on lung stromal cells (CD45-CD31-CD326-). Around 6800 cells were captured using the 10x Chromium technology.
Project description:To investigate the CD140a+ mesenchymal cell heterogeneity in the lung in both steady and tumor-bearing conditions, we utilized CD140aEGFP reporter mice, and purified CD140a+ lung mesenchymal cells from naive and tumor-bearing mice and performed scRNA-seq.
Project description:Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is caused by mutations in SACS gene encoding sacsin. ARSACS patients and mouse models display early degeneration of cerebellum in agreement with high sacsin expression in this organ. We performed unbiased transcriptomic of cerebella from Sacs KO mice versus controls to dissect the mechanisms underlying cerebellar degeneration in ARSACS.
Project description:To investigate heterogeneity of senescence at the single-cell level, we performed scRNA-seq analysis on bone and marrow mesenchymal cells from aged mice
Project description:E9.5 yolk sacs were collected from wild type (CD1) and Cdx-mutant (DKO) embryos and processed for RNA-sequencing to identify Cdx-dependent changes in gene expression
Project description:To identify genes critical for vascular development, we generated mice where ETV2 is inactivated in FLK1+ cells by a loxP-Cre recombination approach. Results provide a detailed insight into the function of ETV2 in emrbyonic vasculare formation. Total RNA obtained from E9.5 yolk sacs from Flk1Cre;ETV2 CKO and control mice.
Project description:Transcriptomic analyses of yolk sacs from mouse embryos at E8.5 was performed to assess the dosage dependent effects of varying Etv2 dosage on early endothelial and hematopoietic development.
